Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy

Drugs Today (Barc). 2004 Oct;40(10):853-63. doi: 10.1358/dot.2004.40.10.863745.

Abstract

This paper reviews the clinical profile of aprepitant, the first neurokinin-1 (NK(1)) receptor antagonist to be approved for use in the prevention of chemotherapy-induced nausea and vomiting. When given to patients receiving highly emetogenic chemotherapy, aprepitant in combination with a 5-hydroxytryptamine type-3 (5HT(3)) receptor antagonist and a corticosteroid provides significantly improved protection from chemotherapy-induced nausea and vomiting over that which has been previously achievable with current antiemetics.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Antiemetics / pharmacology
  • Antiemetics / therapeutic use*
  • Aprepitant
  • Clinical Trials as Topic
  • Drug-Related Side Effects and Adverse Reactions*
  • Humans
  • Morpholines / pharmacology
  • Morpholines / therapeutic use*
  • Nausea / chemically induced*
  • Nausea / prevention & control*
  • Neurokinin-1 Receptor Antagonists*
  • Receptors, Neurokinin-1 / administration & dosage
  • Receptors, Neurokinin-1 / therapeutic use*
  • Vomiting / chemically induced*
  • Vomiting / prevention & control*

Substances

  • Antiemetics
  • Morpholines
  • Neurokinin-1 Receptor Antagonists
  • Receptors, Neurokinin-1
  • Aprepitant